FDA
-
-
-
-
-
-
-
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
-
-
-
-
-
-
-
PROCEPT BioRobotics Corporation (PRCT) Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
-
-
-
-
-
-
-
PROCEPT BioRobotics Corporation (PRCT) Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
-
-
-
-
-
-
-
PROCEPT BioRobotics Corp. Announces United Healthcare Coverage of Aquablation Therapy for Men with Enlarged Prostates
-
-
-
-
-
-
322,900 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

